Clinical Trial Update: Inhaled GM-CSF Therapy of Autoimmune PAP [Phase 2]

View source ↗

Summary

Phase 2 trial assessing inhaled GM-CSF therapy for autoimmune pulmonary alveolar proteinosis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Pulmonary Alveolar Proteinosis

Drugs mentioned

• Sargramostim (GM-CSF) inhalation (granulocyte-macrophage colony-stimulating factor (GM-CSF))

Snippet

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia | Conditions: Autoimmune Pulmonary Alveolar Proteinosis | Phase 2 | Status: COMPLETED | Results posted: 2023-06-26